This article is more than 5 years old. Information may no longer be current.
NCCN awards grants for study of enzalutamide, volasertib
Click Here to Manage Email Alerts
The National Comprehensive Cancer Network awarded research grants to eight investigators.
Five investigators will receive grants to study the effectiveness of enzalutamide (Xtandi; Astellas, Medivation) in mantle cell lymphoma, as well as endometrial, hepatocellular and prostate cancers.
“These five studies selected through peer review represent an excellent mix of both clinical and preclinical projects, which will further elucidate the activity and utility of this important therapeutic agent,” Robert C. Young, MD, interim vice president of the NCCN oncology research program, said in a press release.
Recipients are Albert Chang, MD, PhD, of University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center; Ajay Gopal, MD, of Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; James Harding, MD, of Memorial Sloan Kettering Cancer Center; Gustavo Leone, PhD, of The Ohio State University Comprehensive Cancer Center; and Shannon Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center.
Three investigators will receive grants to study volasertib in hematologic malignancies.
“This award allows researchers from three NCCN member institutions to focus on clinical evaluation of this novel polo-like kinase inhibitor,” Young said in the press release.
Recipients are Anne Beaven, MD, of Duke Cancer Institute; Shira Dinner, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and Steven Gore, MD, of Yale Cancer Center/Smilow Cancer Hospital.